Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BackgroundTesting for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is largely passive, which impedes epidemic control. We defined active testing strategies for SARS-CoV-2 using reverse transcription polymerase chain reaction (RT-PCR) for groups at increased risk of acquiring SARS-CoV-2 in all Canadian provinces.MethodsWe identified 5 groups who should be prioritized for active RT-PCR testing: contacts of people who are positive for SARS-CoV-2, and 4 at-risk populations - hospital employees, community health care workers and people in long-term care facilities, essential business employees, and schoolchildren and staff. We estimated costs, human resources and laboratory capacity required to test people in each group or to perform surveillance testing in random samples.ResultsDuring July 8-17, 2020, across all provinces in Canada, an average of 41 751 RT-PCR tests were performed daily; we estimated this required 5122 personnel and cost $2.4 million per day ($67.8 million per month). Systematic contact tracing and testing would increase personnel needs 1.2-fold and monthly costs to $78.9 million. Conducted over a month, testing all hospital employees would require 1823 additional personnel, costing $29.0 million; testing all community health care workers and persons in long-term care facilities would require 11 074 additional personnel and cost $124.8 million; and testing all essential employees would cost $321.7 million, requiring 25 965 added personnel. Testing the larger population within schools over 6 weeks would require 46 368 added personnel and cost $816.0 million. Interventions addressing inefficiencies, including saliva-based sampling and pooling samples, could reduce costs by 40% and personnel by 20%. Surveillance testing in population samples other than contacts would cost 5% of the cost of a universal approach to testing at-risk populations.InterpretationActive testing of groups at increased risk of acquiring SARS-CoV-2 appears feasible and would support the safe reopening of the economy and schools more broadly. This strategy also appears affordable compared with the $169.2 billion committed by the federal government as a response to the pandemic as of June 2020.

Original publication

DOI

10.1503/cmaj.201128

Type

Journal

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

Publication Date

10/2020

Volume

192

Pages

E1146 - E1155

Addresses

Research Institute of the McGill University Health Centre (Campbell, Oxlade, Fregonese, Menzies, Oh, Bastos, Sulis); Faculty of Medicine (Campbell, Menzies, Winters, Sulis, Uppal, Yanes-Lane, Lan), McGill University; McGill International TB Centre (Campbell, Oxlade, Fregonese, Menzies, Bastos, Sulis, Law); Department of Economics (Laszlo) and School of Population and Global Health (Evans), McGill University, Montréal, Que.; Department of Management Science and Engineering (Russell), Stanford University, Stanford, Calif.; Department of Pediatrics (Oh), Kosin University College of Medicine, Busan, Republic of Korea; Department of Epidemiology (Bastos), Social Medicine Institute, State University of Rio de Janeiro, Rio de Janeiro, Brazil; Department of Global Health and Social Medicine (Law), Harvard Medical School, Boston, Mass.; Département de médicine social et preventive (Brisson), Université Laval, Québec, Que.

Keywords

Humans, Pneumonia, Viral, Coronavirus Infections, Mass Screening, Clinical Laboratory Techniques, Risk Assessment, Risk Factors, Canada, Pandemics, Real-Time Polymerase Chain Reaction, Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Testing